Our data supported this theory when we observed higher levels of IL-6 in the NASH group, accompanied by higher percentages of high-producers of this cytokine in NASH compared to NAFL and the control groups. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.